Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
Abstract
Abstinence from alcohol has been the prevailing treatment goal for individuals with alcohol dependence (AD) within the context of specialty alcohol treatment. Yet, alcohol use has been conceptualized as existing on a continuum. Importantly, most people who meet criteria for AD and could benefit from treatment never receive treatment. About half of these individuals do not seek treatment because they report a desire to continue drinking. To increase acceptability of treatment, reductions in alcohol consumption have been examined as alternative outcomes in treatment trials for AD. The current study reviews data which indicate that long-term reduction in alcohol consumption among patients with AD is possible. Controlled studies have tested reduced alcohol consumption and show sustained improvements in drinking reductions for many patients following behavioral treatments and pharmacotherapy. Evidence-based treatment guidelines and medicines development guidance authorities have taken note of these developments and accept “intermediate harm reduction” (European Medicines Agency) or “low-risk drinking limits” (US Federal Drug Administration) as optional trial endpoints. In conclusion, while abstinence remains the safest treatment goal for individuals with AD, evidence supports that reduced drinking approaches may be an important extension in the treatment of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Treatment gap in mental health care.
Abramowitz, M. Z., Greenberg, D., & Levav, I. (2008) · PubMed · Cited by 1,483
The relation between different dimensions of alcohol consumption and burden of disease: an overview
Rehm, J., Baliunas, D., Borges, G. L. G., Graham, K., Irving, H., Kehoe, T., Parry, C. D., Patra, J., Popova, S., Poznyak, V., et al. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02899.x · Cited by 1,174
Di Castelnuovo, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.22.2437 · Cited by 930
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Research works printed but not linked: 1
- 10.1001/jama.2014.3628 · DOI · Paper page
Cited by
Alcohol use disorder relapse factors: A systematic review.
Sliedrecht, W., de Waart, R., Witkiewitz, K., & Roozen, H. G. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.05.038 · Cited by 358
Self-citationAlcohol use disorders and the heart
Day, E., & Rudd, J. H. F. (2019) · Addiction · doi:10.1111/add.14703 · Cited by 183
Prevention, screening, and treatment for heavy drinking and alcohol use disorder
Knox, J., Hasin, D. S., Larson, F. R. R., & Kranzler, H. R. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30213-5 · Cited by 141
Witkiewitz, K. A., Kranzler, H. R., Hallgren, K. A., O’Malley, S. S., Falk, D. E., Litten, R. Z., Hasin, D. S., Mann, K. F., & Anton, R. F. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13897 · Cited by 152
“Extending treatment options to target reductions in drinking, rather than complete abstinence, could expand the reach of alcohol treatment and have an important impact on public health (Mann et al., 2017; Maremmani et al., 2015; van Amsterdam and van den Brink, 2013).”
Self-citationExpanding the continuum of substance use disorder treatment: Nonabstinence approaches
Paquette, C. E., Daughters, S. B., & Witkiewitz, K. A. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102110 · Cited by 164
Self-citationKiluk, B. D., Fitzmaurice, G. M., Strain, E. C., & Weiss, R. D. (2019) · Addiction · doi:10.1111/add.14289 · Cited by 80
Witkiewitz, K. A., Heather, N., Falk, D. E., Litten, R. Z., Hasin, D. S., Kranzler, H. R., Mann, K. F., O’Malley, S. S., & Anton, R. F. (2020) · Addiction · doi:10.1111/add.15011 · Cited by 84
“Many individuals seeking treatment for alcohol problems prefer non-abstinence goals [7,8] and more individuals may become interested in treatment if drinking reduction goals are included as a treatment target[49,50].”
BackgroundSelf-citationvan den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., et al. (2018) · Addiction Biology · doi:10.1111/adb.12645 · Cited by 75
“In line with these results, a 12-month open comparative study in 86 patients with a VH DRL at baseline showed that sodium oxybate, administered at a dose of 50 mg/kg/day, had a higher abstinence rate (65 percent) than naltrexone 50mg/day (49 percent) (Nava et al. 2006).”
ResultSelf-citationBach, P., Luderer, M., Müller, U. J., Jakobs, M., Baldermann, J. C., Voges, J., Kiening, K., Lux, A., Visser-Vandewalle, V., the DeBraSTRA study group, et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02337-1 · Cited by 65
Self-citationKnox, J., Wall, M., Witkiewitz, K., Kranzler, H. R., Falk, D., Litten, R., Mann, K., O'Malley, S. S., Scodes, J., Anton, R., et al. (2018) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13884 · Cited by 64
Self-citationLee, B. P., Witkiewitz, K. A., Mellinger, J. L., Anania, F. A., Bataller, R. A., Cotter, T. G., Curtis, B. L., Dasarathy, S., DeMartini, K. S., Diamond, I., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00936-x · Cited by 80
Self-citationWitkiewitz, K. A., Falk, D. E., Litten, R. Z., Hasin, D. S., Kranzler, H. R., Mann, K. F., O’Malley, S. S., & Anton, R. F. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14018 · Cited by 65
“More individuals with AUD may be interested in seeking treatment if they are aware of the possibility that drinking reduction goals are achievable, sustainable, and associated with improvements in functioning (Mann et al., 2017; van Amsterdam and van den Brink, 2013).”
BackgroundInfluentialSelf-citationKnox, J., Scodes, J., Wall, M., Witkiewitz, K., Kranzler, H. R., Falk, D., Litten, R., Mann, K., O’Malley, S. S., Anton, R., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.009 · Cited by 54
Self-citationShmulewitz, D., Aharonovich, E., Witkiewitz, K. A., Anton, R. F., Kranzler, H. R., Scodes, J. M., Mann, K. F., Wall, M. M., & Hasin, D. S. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050610 · Cited by 62
Self-citationStability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder
Witkiewitz, K. A., Kranzler, H. R., Hallgren, K. A., Hasin, D. S., Aldridge, A., Zarkin, G. A., Mann, K. F., O’Malley, S. S., & Anton, R. F. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06331-x · Cited by 52
“Thus, a commitment to a goal of abstinence is an extremely high criterion for engaging individuals in treatment for AUD and determining whether alcohol treatment is successful.(3) Drinking reductions, short of abstinence, are associated with considerable improvements in both health and functioning in general populatio…”
BackgroundSelf-citationRigal, L., Sidorkiewicz, S., Tréluyer, J., Perrodeau, É., Jeunne, C. L., Porcher, R., & Jaury, P. (2020) · Addiction · doi:10.1111/add.14927 · Cited by 44
Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease
Knox, J., Scodes, J. M., Witkiewitz, K. A., Kranzler, H. R., Mann, K. F., O’Malley, S. S., Wall, M. M., Anton, R. F., & Hasin, D. S. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14386 · Cited by 35
“If drinking reductions without complete abstinence provide health benefits, then offering treatment options that include non-abstinent drinking reductions might expand interest in treatment (Mann et al., 2017a).”
BackgroundInfluentialSelf-citationAgabio, R., Baldwin, D. S., Amaro, H., Leggio, L., & Sinclair, J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.030 · Cited by 42
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
Lohoff, F. W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.767506 · Cited by 43
“Similarly, naltrexone may be more effective in reducing relapse to heavy drinking than in promoting abstinence (22, 24, 25, 58).”
BackgroundWitkiewitz, K. A., Anton, R. F., O’Malley, S. S., Hasin, D. S., Silverman, B. L., Aldridge, A., Mann, K. F., Kranzler, H. R., Aubin, H., Hoffman, M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2508 · Cited by 40
Self-citationKnox, J., Wall, M. M., Witkiewitz, K. A., Kranzler, H. R., Falk, D. E., Litten, R. Z., Mann, K. F., O’Malley, S. S., Scodes, J. M., Anton, R. F., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.03.020 · Cited by 37
Self-citationNovel medications for problematic alcohol use
Heilig, M. A., Witkiewitz, K. A., Ray, L. A., & Leggio, L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172889 · Cited by 29
“There is also a growing consensus in the field that reduced drinking is an acceptable treatment outcome for AD (23, 43).”
Self-citationImproving alcohol health literacy and reducing alcohol consumption: recommendations for Germany
Manthey, J., Kokole, D., Riedel-Heller, S. G., Rowlands, G., Schäfer, I., Schomerus, G., Soellner, R., & Kilian, C. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00383-0 · Cited by 35
“Here, sufficient capacities for supporting the patient in achieving abstinence or other treatment goals [47] are required and should be planned ahead, including medications for withdrawal treatment, as well as psychosocial support [42, 48].”
BackgroundProspects of GLP-1 Therapies for Addiction and Mental Health Comorbidities—Quo Vadis? A Review
Farokhnia, M., & Leggio, L. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4308 · Cited by 33
Berglund, K. J., Rauwolf, K. K., Berggren, U., Balldin, J., & Fahlke, C. (2019) · Alcohol and Alcoholism · doi:10.1093/alcalc/agz042 · Cited by 22
“Traditionally, the drinking goal for treatment of alcohol dependence in European countries has focused on abstinence from alcohol as the most central and acceptable treatment outcome (Mann et al., 2017).”
BackgroundIngesson, S., Finn, S. W., Rosendahl, I. K., Andréasson, S., Jayaram‐Lindström, N., & Hammarberg, A. (2023) · Addiction · doi:10.1111/add.16325 · Cited by 26
Schückher, F., Sellin, T., Engström, I., & Berglund, K. J. (2019) · BMC Women s Health · doi:10.1186/s12905-019-0857-4 · Cited by 24
A Critical Review of Qualitative Interview Studies with Alcoholics Anonymous Members
Glassman, H. S., Rhodes, P., & Buus, N. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1681450 · Cited by 23
Blondino, C., Gormley, M. A., Taylor, D. D. H., Lowery, E. P., Clifford, J. S., Burkart, B., Graves, W. C., Lü, J., & Prom‐Wormley, E. C. (2020) · Epidemiologic Reviews · doi:10.1093/epirev/mxaa005 · Cited by 22
Witkiewitz, K. A., Morris, J. K., & Tucker, J. A. (2021) · Addiction · doi:10.1111/add.15429 · Cited by 21
Self-citationClinical neuroscience of addiction: what clinical psychologists need to know and why
Ray, L. A., & Grodin, E. N. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081219-114309 · Cited by 18
Witkiewitz, K. A., Kirouac, M., Roos, C. R., Wilson, A. D., Hallgren, K. A., Bravo, A. J., Montes, K. S., & Maisto, S. A. (2018) · Psychology of Addictive Behaviors · doi:10.1037/adb0000381 · Cited by 23
Self-citationHell, M. E., & Nielsen, A. S. (2020) · Addiction Research & Theory · doi:10.1080/16066359.2020.1723083 · Cited by 23
“These outcome measures are chosen because they are clinically meaningful; treatment success is usually measured by reduced drinking and/or improved quality of life (Frischknecht et al. 2013; Mann et al. 2017).”
BackgroundLahbairi, N., Lanièpce, A., Segobin, S. H., Cabé, N., Boudehent, C., Vabret, F., Rauchs, G., & Pitel, A. (2022) · Health and Quality of Life Outcomes · doi:10.1186/s12955-022-02058-x · Cited by 16
Xin, Y., España, M., & Davis, A. K. (2022) · Journal of Social Work Practice · doi:10.1080/02650533.2022.2034768 · Cited by 18
“moderate consumption) as an outcome goal and offering moderation training in SUD treatment settings (Ambrogne, 2002; Mann et al., 2017; Van Amsterdam & Van den Brink, 2013; Walters, 2000).”
BackgroundKranzler, H. R., Hartwell, E. E., Feinn, R., Pond, T., Witkiewitz, K. A., Gelernter, J. E., & Crist, R. C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108762 · Cited by 14
Self-citationWorld Health Organization risk drinking levels as a treatment outcome measure in topiramate trials
Hartwell, E. E., Feinn, R., Witkiewitz, K. A., Pond, T., & Kranzler, H. R. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14652 · Cited by 14
Self-citationGreene, M. C., Kane, J., Alto, M., Giusto, A., Lovero, K., Stockton, M., McClendon, J., Nicholson, T., Wainberg, M. L., Johnson, R. M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013350.pub2 · Cited by 11
Quadri, M. F. A., Lusher, J. M., Foláyan, M. O., Tantawi, M. E., Zúñiga, R. A. A., Brown, B. J., Aly, N. M., Okeibunor, J., Abeldaño, G. F., Jafer, M. A., et al. (2023) · Tobacco Induced Diseases · doi:10.18332/tid/157205 · Cited by 13
Nieto, S. J., Enders, C. K., Witkiewitz, K. A., O’Malley, S. S., & Ray, L. A. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14953 · Cited by 10
Self-citationCombined pharmacological and psychosocial interventions for alcohol use disorder
Minozzi, S., Rosa, G. R. M. L., Salis, F., Camposeragna, A., Saulle, R., Leggio, L., & Agabio, R. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015673.pub2 · Cited by 22
Reduced drinking and harm reduction in the treatment of alcohol use disorders
Bischof, G., Lange, N., Rumpf, H., & Preuss, U. W. (2020) · Drugs and Alcohol Today · doi:10.1108/dat-10-2020-0063 · Cited by 12
Finn, S. W., Hammarberg, A., Andréasson, S., & Jirwe, M. (2021) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2021.1882079 · Cited by 11
“To offer treatment goals beyond the traditional focus on abstinence only is one important factor in broadening the focus for treatments for AUD, and also improving treatment seeking [1,18].”
BackgroundGrundinger, N., Gerhardt, S., Karl, D., Mann, K. F., Kiefer, F., & Vollstädt‐Klein, S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06137-1 · Cited by 14
Self-citationThe Central Role of Lifelong Learning and Humility in Clinical Psychology
Washburn, J. J., Teachman, B. A., Gaudiano, B. A., Penberthy, J. K., Peris, T. S., Davison, G. C., & Hollon, S. D. (2022) · Clinical Psychological Science · doi:10.1177/21677026221101063 · Cited by 9
Mejldal, A., Andersen, K., Behrendt, S., Bilberg, R., Bogenschutz, M. P., Braun‐Michl, B., Bühringer, G., & Nielsen, A. S. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14562 · Cited by 10
Roozen, H. G., Bravo, A. J., Pilatti, A., Mezquita, L., Vingerhoets, A. J. J. M., & Cross-cultural Addictions Study Team (2020) · Current Psychology · doi:10.1007/s12144-020-00818-w · Cited by 12
Richards, D. K., Tuchman, F. R., Hallgren, K. A., Kranzler, H. R., Aubin, H., O’Malley, S. S., Mann, K. F., Aldridge, A., Anton, R. F., & Witkiewitz, K. A. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001303 · Cited by 7
Self-citationBischof, G., Lange, N., Rumpf, H., & Preuss, U. W. (2019) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000596 · Cited by 9
Körkel, J. (2021) · Drugs and Alcohol Today · doi:10.1108/dat-10-2020-0065 · Cited by 7
Batra, A. (2023) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000838 · Cited by 7
Repurposing drugs for treatment of alcohol use disorder
Aubin, H. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.02.002 · Cited by 9
Self-citationVotaw, V. R., & Witkiewitz, K. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_20 · Cited by 9
Self-citationAubin, H., Berlin, I., Guiraud, J., Bruhwyler, J., Batel, P., Perney, P., Trojak, B., Bendimerad, P., Guillou-Landréat, M., Bisch, M., et al. (2024) · Addiction · doi:10.1111/add.16484 · Cited by 6
Self-citationLevak, S., Kuerbis, A., & Morgenstern, J. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.01.001 · Cited by 7
Aubin, H., Dureau‐Pournin, C., Falissard, B., Paillé, F., Rigaud, A., Micon, S., Pénichon, M., Andersohn, F., Truchi, C., & Blin, P. (2021) · Alcohol and Alcoholism · doi:10.1093/alcalc/agab029 · Cited by 5
“Despite the associated high level of disease burden, it has been estimated that only 10% of European patients with alcohol dependence receive the treatment they need (Rehm et al., 2013; Mann et al., 2017).”
Self-citationSchwebel, F. J., Emery, N. N., Pfund, R. A., Pearson, M. R., & Witkiewitz, K. A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108825 · Cited by 7
Self-citationStevenson, B. L., Anker, J. J., THURAS, P. D., Rinehart, L., & Kushner, M. G. (2022) · Psychology of Addictive Behaviors · doi:10.1037/adb0000895 · Cited by 5
Vest, N. A., Rossi, F. S., Ilgen, M. A., Humphreys, K. N., & Timko, C. (2021) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2021.82.792 · Cited by 5
Miyake, N., So, R., Kariyama, K., Itagaki, Y., Yamagishi, T., Wakuta, A., Nishimura, M., Murakami, S., Ogawa, M., Takebayashi, Y., et al. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.07.003 · Cited by 5
Schallenberg, M., Pilhatsch, M., Petzold, J., Vogel, D., Zimmermann, U. S., & Spreer, M. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00522-1 · Cited by 4
Cognitive Behavioral Therapy for Social Anxiety Disorder and Alcohol Use Disorder
Stapinski, L. A., Gückel, T., Kelly, E. V., & Prior, K. (2024) · CBT: science into practice · doi:10.1007/978-3-031-62971-6_2 · Cited by 4
Vest, N. A., Harris, A. H. S., Ilgen, M. A., Humphreys, K. N., & Timko, C. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14474 · Cited by 3
“Recent empirical reviews indicate that, even among those patients with established alcohol use disorders, significant reductions in alcohol use without achieving full abstinence were associated with improved long-term functional outcomes (Mann et al., 2017; Witkiewitz and Tucker, 2020).”
BackgroundHeather, N. (2020) · Alcohol and Alcoholism · doi:10.1093/alcalc/agaa137 · Cited by 4
Aubin, H., & Mann, K. F. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13909 · Cited by 2
Self-citationPhimarn, W., Chamnanjit, P., Anunworapunya, W., Saramunee, K., & Sungthong, B. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.905 · Cited by 3
“In addition, we conducted subgroup analyses based on the dose of baclofen, duration of treatments and risk associated with a specified alcohol consumption level[27].”
von Greiff, N., & Skogens, L. (2020) · Drugs and Alcohol Today · doi:10.1108/dat-12-2019-0051 · Cited by 5
Metodología utilizada para estimar la mortalidad atribuible a alcohol en España, 2001-2017
Donat, M., Sordo, L., Guerras, J. M., Politi, J., Pulido, J., & Barrio, G. (2021) · Adicciones · doi:10.20882/adicciones.1611 · Cited by 2
Vom Abstinenzmonopolismus zur zieloffenen Behandlung suchtbelasteter Menschen
Körkel, J. (2023) · PiD - Psychotherapie im Dialog · doi:10.1055/a-1959-4785 · Cited by 1
Lee, M. L., Jack, H. E., Matson, T. E., Oliver, M. M., Bobb, J. F., Berger, D. B., Bradley, K. A., & Hallgren, K. A. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70125 · Cited by 1
Witkiewitz, K. A., Tucker, J. A., Hayes, T., Kuhlemeier, A., Aldridge, A., & Vuchinich, R. E. (2026) · Journal of the Experimental Analysis of Behavior · doi:10.1002/jeab.70125 · Cited by 1
“Most people who meet AUD criteria never receive alcohol treat-ment (Mann et al., 2017; Nadkarni et al., 2023; Witkiewitz et al., 2019).”
Self-citationGarcia‐Rivas, V., Soares, A. R., Thomas, M. A., Na, J. J., Smith, A., Picciotto, M. R., & Mineur, Y. S. (2024) · Alcohol · doi:10.1016/j.alcohol.2024.12.004 · Cited by 1
Conquering the Craving: Treatment to Curb Alcohol Use Disorder
Umhau, J. C. (2019) · Journal of Christian Nursing · doi:10.1097/cnj.0000000000000624 · Cited by 2
New: The European Addiction Research Award
Service, M. P., Stückle, D., & Stückle, D. (2017) · European Addiction Research · doi:10.1159/000485731
Ghosh, A., Mahintamani, T., & Choudhury, S. (2020) · Addiction · doi:10.1111/add.15172
Predictors for Abstinence in Socially Stable Women Receiving Treatment for Alcohol Use Disorder
Schückher, F., Berglund, K. J., Engström, I., & Sellin, T. (2022) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2021.2018957
“Given that abstinence from alcohol is the safest option for individuals with AUD, the outcome was abstinence at a 12-month follow-up (Berglund et al., 2019; Mann et al., 2017; Meyer et al., 2014).”
BackgroundResultField, M., & Kersbergen, I. (2019) · Addiction · doi:10.1111/add.14854
Hmara, N. V., & Skugarevsky, O. (2023) · Health and Ecology Issues · doi:10.51523/2708-6011.2022-19-4-09
Bach, P. (2023) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-023-3169-z
Evidence-Based Behavioral Treatments
Hammarberg, A., & Ingesson, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_15 · Cited by 2
Hemrage, S., Parkin, S., Deluca, P., & Drummond, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4471569/v1
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
von Greiff, N., & Skogens, L. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2025.2506416 · Cited by 3
“There is evidence supporting the notion that complete abstinence is a safer path during the early stages of the recovery process (Booth, 2006; Coldwell & Heather, 2006; Mann et al., 2017).”
ALCOHOL AND THE HEART: THE ROLE OF ETHANOL IN THE DEVELOPMENT OF CARDIOMYOPATHY AND HEART FAILURE
Błaszkiewicz, M., Kośka, J., Łocik, G., Moliszewska, K., Kukiełka, P., Mazurek, J., Załęcka, J., Nowik, A., Dywan, K., & Musiorska, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3621
Gunasekaran, D. M., Binu, V. S. N., Kandasamy, A., Sethuraman, L., & Bhaskarapillai, B. (2025) · Research Square · doi:10.21203/rs.3.rs-7489427/v1
Lindrio, C. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i12.2182
Buckheit, K. A., Firkey, M. K., Sedotto, R. N. M., Simpson, T. L., Mastroleo, N. R., Scharer, J. L., Maisto, S. A., & Possemato, K. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2606865
“There is ongoing discourse around the practice of harm reduction versus abstinence in alcohol treatment, with support for the effectiveness of both approaches (Dennis et al., 2020; Mann et al., 2017; Stockwell et al., 2018).”
Nomura, N., Uojima, H., Asakura, T., Sawayama, E., Dezumi, R., Iida, J., Iwasaki, S., Hidaka, H., Tanaka, Y., Inada, K., et al. (2026) · Internal Medicine · doi:10.2169/internalmedicine.6643-25 · Cited by 1
“By integrating AUDIT into routine practice, hepatologists can efficiently stratify risks and provide structured, tiered interventions (15).”
Addiction : rôle et pratiques en soins primaires des médecins généralistes en 2026
Jaury, P. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.06.005
Vargas-Malebrán, N., & Loayza, L. S. (2026) · Revista Colombiana de Psicología · doi:10.15446/rcp.v35n2.116517
“This is in line with previous research (Howarth et al., 2020; Milner et al., 2018) and models (Mann et al., 2017; Soloff et al., 2008; Stoelb & Chiriboga, 1998).”
Körkel, J. (2026) · Edition Forschung und Entwicklung in der Strafrechtspflege · doi:10.1007/978-3-658-50412-0_16
Metadata
- Authors
- Mann, K., Aubin, H.-J., & Witkiewitz, K.
- Affiliations
- Heidelberg University (DE)
- Université Paris-Sud (FR)
- University of New Mexico (US)
- Venue
- European Addiction Research
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 23
- Issue
- 5
- Pages
- 219-230
- ISSN
- 1022-6877 (ISSN-L)
- 1421-9891
- OpenAlex
- W2759499582
- Cited by
- 93
- References
- 110
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 11 · 2023: 12 · 2022: 10 · 2021: 13 · 2020: 12 · 2019: 14 · 2018: 6 · 2017: 1
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- European Addiction Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- alcoholism, harm reduction, abstinence, treatment outcomes, behavior therapy, pharmacotherapy, treatment acceptability, treatment-seeking behavior
- MeSH terms
- Alcohol Drinking, Alcoholism, Female, Humans, Male, Behavior, Addictive, Treatment Outcome, Harm Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.